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418REPLY: Intravascular Ultrasound–Guided PCI
Undervalued Since its InceptionWe appreciate Dr. Garcia-Garcia and colleagues for
their valuable comments on our paper (1). Endeavor
zotarolimus-eluting stent can be considered an
“early-generation” drug-eluting stent (DES) along
with ﬁrst-generation DES (Cypher [Cordis, Milpitas,
California] and Taxus [Boston Scientiﬁc, Natick,
Massachusetts]), when classiﬁed into early-
generation and new-generation according to the
European Society of Cardiology/European Associa-
tion of Percutaneous Cardiovascular Interventions
report. However, considering that the safety of ﬁrst-
generation DES has been questioned because of sub-
optimal biocompatibility of durable polymers, and
the next-generation DES were developed with the
novel durable or biodegradable polymeric drug
carrier systems, the Endeavor zotarolimus-eluting
stent (Medtronic, Dublin, Ireland) coated with a
biocompatible polymer (phosphorylcholine) may not
be positioned as the same category of ﬁrst-generation
DES. Although the deﬁnition of “new-generation” can
be confusing, in this meta-analysis, we ﬁrst searched
the randomized trials treated with DES and excluded
5 trials with ﬁrst-generation DES.
Regarding the choice of major cardiovascular
event (MACE), the impact of intravascular ultra-
sound (IVUS) guidance on clinical outcomes partic-
ularly of “the local coronary treatment” has already
been reported in the IVUS-XPL (Impact of Intra-
vascular Ultrasound Guidance on Outcomes of
Xience Prime Stents in Long Lesions) trial, and
patients with IVUS guidance had a 48% reduction in
the 1-year MACE rate, primarily due to the lower
risk of target lesion revascularization (TLR) (2).
However, in this trial, the between-group differ-
ences in cardiac death or myocardial infarction were
not different. Thus, the primary objective of this
meta-analysis focused on the “hard” clinical out-
comes, and the MACE, even not adding the TLR
events, was lower in the IVUS-guidance group.
The reduction of TLR was also conﬁrmed in this
meta-analysis.
In the IVUS-XPL trial, IVUS criteria for stent opti-
mization were deﬁned as a minimal lumen cross-
sectional area greater than the lumen cross-sectional
area at distal reference segments, and 54%
(363 of 678) of patients met the criteria (2). In the
RESET (REal Safety and Efﬁcacy of 3-month dualantiplatelet Therapy following Endeavor zotarolimus-
eluting stent implantation-Long)-Long substudy,
49% (126 of 256) of patients met these criteria (3). In
the CTO-IVUS (Chronic Total Occlusion InterVention
with drUg-eluting Stents guided by IVUS) trial, 60%
(117 of 196) of patients met the following criteria:
1) minimal stent area $ distal reference lumen area;
2) stent area at chronic total occlusion segment
$5 mm2 as far as vessel area permits; and 3) com-
plete stent apposition (4). Overall, 606 (54%)
patients met the IVUS criteria among 1,130 patients
who underwent IVUS in the IVUS-guided group.
MACE (a composite of cardiac death, myocardial
infarct, and stent thrombosis) was signiﬁcantly
lower in the patients who met the IVUS criteria
versus those who did not meet the IVUS criteria
(0% vs. 1.0%; p ¼ 0.016).
In conclusion, IVUS-guided new-generation DES
implantation was associated with favorable outcomes
of “hard” MACE in long lesions or chronic total oc-
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